[PDF][PDF] Phase III double-blind placebo-controlled study of farnesyl transferase inhibitor R115777 in patients with refractory advanced colorectal cancer
S Rao, D Cunningham, A De Gramont… - Journal of Clinical …, 2004 - Citeseer
S Rao, D Cunningham, A De Gramont, W Scheithauer, M Smakal, Y Humblet, G Kourteva…
Journal of Clinical Oncology, 2004•CiteseerPhase III Double-Blind Placebo-Controlled Study of Farnesyl Transferase Inhibitor R115777
in Patients With Refractory Advanced C Page 1 Phase III Double-Blind Placebo-Controlled
Study of Farnesyl Transferase Inhibitor R115777 in Patients With Refractory Advanced
Colorectal Cancer S. Rao, D. Cunningham, A. de Gramont, W. Scheithauer, M. Smakal, Y.
Humblet, G. Kourteva, T. Iveson, T. Andre, J. Dostalova, A. Illes, R. Belly, JJ Perez-Ruixo,
YC Park, and PA Palmer A B S T R A C T Purpose To determine whether R115777 …
in Patients With Refractory Advanced C Page 1 Phase III Double-Blind Placebo-Controlled
Study of Farnesyl Transferase Inhibitor R115777 in Patients With Refractory Advanced
Colorectal Cancer S. Rao, D. Cunningham, A. de Gramont, W. Scheithauer, M. Smakal, Y.
Humblet, G. Kourteva, T. Iveson, T. Andre, J. Dostalova, A. Illes, R. Belly, JJ Perez-Ruixo,
YC Park, and PA Palmer A B S T R A C T Purpose To determine whether R115777 …
Purpose
To determine whether R115777 improves survival in patients with refractory advanced colorectal cancer (CRC) in a multicenter, double-blind, prospective randomized study.
Citeseer